Tesofensine
A small-molecule drug that raises serotonin, noradrenaline and dopamine signaling and suppresses appetite. Studied for obesity.
Investigational in most countries, including the US.
Look it up on Wikipedia13 listings across 8 independently tested vendors, ranked by price per milligram after coupon codes anyone can use. Vendors you can only order from by message are hidden.
Some links here are affiliate links: if you buy through one, this site may earn a commission at no extra cost to you. Prices, rankings and plans are worked out the same way whether or not a vendor pays one.
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it.
Daily price tracking started October 7, 2026; a price-history chart appears here once a few days have been collected.
| Vendor | Trust | Listing | Vials | Price | Per mg | |
|---|---|---|---|---|---|---|
Peptide Group Buy PGB #39 by metascore · US |
Tesofensine 500mcg (120 tabs) | 120 × 500 mcg = 60 mg | $65.00 $0.54 per vial |
$1.08 | Buy | |
Pure Tested Peptides #109 by metascore · US |
Tesofensine 500mcg — 6 bottles | 600 × 500 mcg = 300 mg | $999.99 $1.67 per vial |
$3.33 | Buy | |
Pure Tested Peptides #109 by metascore · US |
Tesofensine 500mcg — 4 bottles | 400 × 500 mcg = 200 mg | $699.99 $1.75 per vial |
$3.50 | Buy | |
Pure Tested Peptides #109 by metascore · US |
Tesofensine 500mcg — 3 bottles | 300 × 500 mcg = 150 mg | $549.99 $1.83 per vial |
$3.67 | Buy | |
Pure Tested Peptides #109 by metascore · US |
Tesofensine 500mcg — 2 bottles | 200 × 500 mcg = 100 mg | $389.99 $1.95 per vial |
$3.90 | Buy | |
Pure Tested Peptides #109 by metascore · US |
Tesofensine 500mcg — 1 bottle | 100 × 500 mcg = 50 mg | $199.00 $1.99 per vial |
$3.98 | Buy | |
Orbitrex Peptides #1 by metascore · US |
Metascore 90Finnrick 71%Bought vials 104% of label · 27 testsTitrateLab · PeptideBase · Peptide CriticNo report for thisOnline checkout |
Tesofensine 500mcg | 60 × 500 mcg = 30 mg | $129.99 $2.17 per vial |
$4.33 | Buy |
PurePEPS #184 by metascore |
Metascore 73Finnrick 44%Bought vials 108% of label · 10 testsTitrateLabNo public reportsOnline checkout |
TESOFENSINE – 25mg | 50 × 500 mcg = 25 mg | $112.99 $2.26 per vial |
$4.52 | Buy |
Royal Peptides Affiliate #8 by metascore · US |
Metascore 86Finnrick 75%Bought vials 107% of label · 34 testsTitrateLabNo report for thisConfirmed with lab: 3 of 3Online checkout |
Tesofensine 500mcg 100/ bottle (wholesale) 10% off with code |
1 × 500 mcg | 10% off with code |
$162.00 list $180.00 |
Buy |
Modern Aminos Affiliate #125 by metascore · US |
Metascore 75 medium confidenceFinnrick 79%PepIndex 81/100Bought vials 100% of label · 5 testsTitrateLab · PeptideBase · Peptide CriticNo report for thisOnline checkout |
Tesofensine 500MCG Dry-Fill $30 off through this site's link (new customers) |
1 × 500 mcg | $139.00 $30 off through this site's link (new customers) |
$278.00 | Buy |
Simple Peptide #25 by metascore · US, FL 33446 |
Metascore 83Finnrick 62%PepIndex 82/100Bought vials 100% of label · 44 testsTitrateLabNo report for thisOnline checkout |
Tesofensine | 1 × 500 mcg | $150.00 | $300.00 | Buy |
Modern Aminos Affiliate #125 by metascore · US |
Metascore 75 medium confidenceFinnrick 79%PepIndex 81/100Bought vials 100% of label · 5 testsTitrateLab · PeptideBase · Peptide CriticNo report for thisOnline checkout |
Tesofensine 250MCG Dry-Fill $30 off through this site's link (new customers) |
1 × 250 mcg | $79.00 $30 off through this site's link (new customers) |
$316.00 | Buy |
Hydro Research #105 by metascore |
Metascore 75 medium confidenceFinnrick 51%PepIndex 86/100Bought vials 123% of label · 4 testsTitrateLabNo report for thisOnline checkout |
Tesofensine 100mcg | 1 × 100 mcg | $60.00 | $600.00 | Buy |
Mixing a 0.5 mg vial
What each common amount of bacteriostatic water gives you on a U-100 insulin syringe. Pick a vial size above to change it.
| Water | Strength | Per 10 units (0.1 mL) | Per unit |
|---|---|---|---|
| 1 mL | 0.5 mg/mL | 50 mcg | 5 mcg |
| 2 mL | 0.25 mg/mL | 25 mcg | 2.5 mcg |
| 3 mL | 0.167 mg/mL | 16.7 mcg | 1.67 mcg |
| 5 mL | 0.1 mg/mL | 10 mcg | 1 mcg |
Published lab results
3 certificates of analysis that vendors publish for Tesofensine. Numbers are only filled in where the document is readable text; image-only COAs are linked without numbers. A vendor's own COA shows one tested sample, not every batch.
| Vendor | Lab | Date | Label | Measured | Purity | Batch | |
|---|---|---|---|---|---|---|---|
Peptide Group Buy PGB |
Janoshik | 2026-07-01 | – | – | – | PSTES500U-1 (Round 1) | View |
LN PeptidesCOA note |
– | 2026-03-11 | – | – | – | View (image) | |
Verified Peptides |
– | – | – | – | – | View (image) |
Doses studied in research Studied in people
What was given to people (or animals) in published studies and official labels, each linked to its source. This is not a recommendation: study products, purity and supervision differ from research-grade vials.
| Who was studied | Dose given | How often | For how long | What happened | |
|---|---|---|---|---|---|
| adults with obesity (BMI 30-40) on an energy-restricted diet (phase 2) n = 203 |
0.25, 0.5 or 1.0 mg oral | once daily | 24 weeks | mean weight loss 4.5% / 9.2% / 10.6% vs 2.0% placebo; heart rate +7.4 beats/min at 0.5 mg | PubMed |
| patients with Parkinson's or Alzheimer's disease (pooled 4 RCTs, no diet program) n = 968 |
0.125, 0.25, 0.5 or 1.0 mg oral | once daily | 14 weeks | weight change -0.5% to -2.8% vs +0.5% placebo, dose-dependent | PubMed |
| patients with advanced Parkinson disease and motor fluctuations | 0.125, 0.25, 0.5 or 1 mg oral (tablets) | once daily | 14 weeks | modest motor improvements at single doses without a dose-response; more GI and neuropsychiatric adverse events at higher doses | PubMed |
| adults with obesity n = 158 |
0.25, 0.5 or 1.0 mg | once daily | 24 weeks (plus extension at 0.5 or 1.0 mg) | increased satiety at 12 weeks that waned by 24 weeks | PubMed |
Not approved by FDA or EMA. The 24-week obesity trial later received a Lancet expression of concern. Tesofensine is a small molecule, not a peptide.
What the research says
Tesofensine (a small-molecule triple monoamine reuptake inhibitor, not a peptide) produced about 4.5-10.6% weight loss vs 2% with placebo in one 24-week phase 2 RCT of 203 people and modest weight loss in pooled neurology trials, but it raises heart rate, the key obesity trial later received a Lancet expression of concern, and a letter flagged under-reporting of its adverse effects; no phase 3 results appear in the candidates.
Key papers ✓ 1~ 5? 2
-
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.Humans203 peopleRandomizedPlacebo-controlledDouble-blind24 weeksPhase II randomised, double-blind, placebo-controlled trial
In 203 obese adults on a diet, 24 weeks of tesofensine gave 4.5-10.6% weight loss vs 2.0% with placebo, but heart rate rose by 7.4 beats/min at 0.5 mg; dry mouth, nausea, constipation, diarrhea and insomnia were common.
Key resultMean weight loss 2.0% with diet and placebo vs 4.5%, 9.2% and 10.6% with tesofensine 0.25, 0.5 and 1.0 mg (p<0.0001); heart rate rose 7.4 beats per min with 0.5 mg (p=0.0001)
Study details
- Studied
- Obese patients (BMI 30 to 40 kg/m2) in five Danish centres, on an energy-restricted diet
- Compared with
- Placebo plus diet
- Main outcome
- Percentage change in bodyweight
- Sample
- 203 obese patients randomized (placebo n=52; tesofensine 0.25 mg n=52, 0.5 mg n=50, 1.0 mg n=49); 161 completed
- Authors' conclusion
- Tesofensine 0.5 mg might produce weight loss twice that of currently approved drugs, but efficacy and safety need confirmation in phase III trials.
- Limitations
- Phase II; 21% did not complete; raised heart rate and frequent GI/sleep adverse events.
-
Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.No new data
The Lancet published a formal expression of concern about the 2008 tesofensine obesity trial (no abstract available).
Study details
- Authors' conclusion
- An expression of concern was published about the 2008 tesofensine obesity trial (title only; no abstract available).
- Limitations
- No abstract available; details of the concern are not given here.
-
Under-reporting of adverse effects of tesofensine.No new data
Letter titled as raising under-reporting of tesofensine's adverse effects (no abstract available).
Study details
- Authors' conclusion
- A published letter on under-reporting of adverse effects of tesofensine (title only; no abstract available).
- Limitations
- No abstract available.
-
Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.Humanssize not reported4 trials pooledRandomized trials14 weeksMeta-analysis of four randomized, double-blind, multicenter trials
Pooling 4 RCTs (968 patients) without any diet program, 14 weeks of tesofensine gave dose-dependent weight loss up to about 4% vs placebo, with heart rate rising up to 6.8 beats/min.
Key resultWeight change after 14 weeks was +0.5, -0.5, -0.9, -1.8, -2.8% with placebo and 0.125, 0.25, 0.5, 1.0 mg tesofensine (P = 0.015 for dose effect); heart rate rose up to 6.8 bpm, no effect on blood pressure
Study details
- Studied
- Patients with Parkinson's or Alzheimer's disease in trials of tesofensine
- Compared with
- Placebo
- Main outcome
- Change in body weight
- Sample
- Meta-analysis of 4 randomized trials (tesofensine n=740, placebo n=228)
- Authors' conclusion
- Tesofensine produced placebo-subtracted weight loss of about 4% over 14 weeks without diet or lifestyle therapy, similar to sibutramine but without a blood pressure effect.
- Limitations
- Patients had neurodegenerative disease, not obesity; only 14-21% were obese.
-
The effect of tesofensine on appetite sensations.Humans158 peopleRandomizedPlacebo-controlledDouble-blindTwo 24-week parts separated by a 12-week drug-free periodPhase II trial: Part 1 randomized double-blind placebo-controlled; Part 2 open-label single-group
In 158 obese adults, tesofensine increased satiety at 12 weeks, but this effect waned by 24 weeks and returned to baseline after stopping.
Key resultTesofensine dose-dependently increased composite satiety score at week 12, correlating with weight loss (r = 0.36, P < 0.0001); the score diminished over time and returned to baseline after withdrawal
Study details
- Studied
- Participants in a multicentre phase II obesity trial
- Compared with
- Placebo (Part 1)
- Main outcome
- Appetite sensations and composite satiety score
- Sample
- 158 participants in Part 1; 113 in Part 2
- Authors' conclusion
- Enhanced satiety may be involved in early weight loss; it is unclear whether the attenuated appetite effect after 24 weeks reflects the weight-reduced state or diminishing drug effect.
- Limitations
- Part 2 was open-label and uncontrolled.
-
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.Humanssize not reportedRandomizedPlacebo-controlledDouble-blind14 weeksPilot phase 2 randomized, double-blind, placebo-controlled, parallel-group trial (ADVANS)
In advanced Parkinson disease, tesofensine gave modest motor improvements at single doses without a dose-response, and GI and neuropsychiatric adverse events were more frequent, especially at higher doses.
Key resultDifference vs placebo of -4.7 points in UPDRS II+III with 0.5 mg (P =.005) and -7.1% in off time with 0.25 mg (P =.02); other dosages not significant
Study details
- Studied
- Patients with advanced Parkinson disease and levodopa-related motor fluctuations
- Compared with
- Placebo
- Main outcome
- UPDRS subscale II plus III score and percentage of waking hours in off time
- Authors' conclusion
- Patients showed modest improvements, but no dose-response could be established for efficacy and adverse reactions tended to be more frequent at higher dosages.
- Limitations
- Pilot trial; no clear dose-response; GI and neuropsychiatric adverse events more common.
-
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.Humans52 peopleRandomizedPlacebo-controlledDouble-blindMeasures for 48 h after each doseSingle-dose, randomized, double-blind, crossover study
In 52 recreational stimulant users, single-dose tesofensine had abuse-related effects no different from placebo and lower than amphetamine, suggesting low abuse potential.
Study details
- Studied
- Recreational stimulant users
- Compared with
- Placebo, D-amphetamine (positive control), bupropion, atomoxetine
- Main outcome
- Subjective and objective abuse-related effects
- Sample
- 52 recreational stimulant users (crossover)
- Authors' conclusion
- Tesofensine effects were not significantly different from placebo and abuse potential was no greater than bupropion or atomoxetine; it is unlikely to be recreationally abused.
- Limitations
- Single dose in recreational stimulant users.
-
Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.Animalssize not reportedAcute administrationCombined food intake and cardiovascular telemetry study of tesofensine with metoprolol or telmisartan
In rats, tesofensine suppressed food intake but raised heart rate and blood pressure via sympathetic activation; metoprolol blocked the cardiovascular effects without reducing appetite suppression.
Study details
- Studied
- Telemetrized conscious rats
- Compared with
- Tesofensine alone vs combined with metoprolol or telmisartan
- Main outcome
- Food intake, heart rate and blood pressure
- Authors' conclusion
- Metoprolol fully prevented cardiovascular effects of tesofensine without affecting its reduction of food intake; telmisartan only partly reversed the blood pressure rise. Sympathetic activity appears to drive the cardiovascular effects.
- Limitations
- Acute rat study.
Reported side effects
- reportedIncreased heart rate [ref] [ref]
- commonDry mouth, nausea, constipation, diarrhea [ref]
- commonInsomnia [ref]
- reportedNeuropsychiatric adverse events (higher doses) [ref]
The main obesity trial is under a Lancet expression of concern, and adverse effects may have been under-reported.
11 registered human trials (0 active)
✓ positive · ✗ negative · ~ mixed · ? inconclusive, judged on each paper's own main outcome. Grades: A strong human evidence → D little or none. Papers and verdicts are drawn from PubMed, Europe PMC and Russian journals (CyberLeninka); not medical advice.
Registered clinical trials 11 on ClinicalTrials.gov · 0 active · 11 completed · 4 with posted results
All 11 Tesofensine trials, with countries and summaries · Search ClinicalTrials.gov · Recruiting trials for every peptide
Discussions elsewhere
Experiences and questions about Tesofensine on other sites. Treat anecdotes with care.
Tesofensine: questions people ask
What is Tesofensine?
Monoamine reuptake inhibitor (not a peptide). A small-molecule drug that raises serotonin, noradrenaline and dopamine signaling and suppresses appetite. Studied for obesity.
How much does Tesofensine cost?
The cheapest Tesofensine from an independently tested vendor is $1.08 per mg (Peptide Group Buy PGB, Tesofensine 500mcg (120 tabs), $65.00). Across 13 listings from 8 vendors the median is $4.33 per mg.
Where can I buy Tesofensine?
8 vendors tested by Finnrick sell Tesofensine. The cheapest per mg right now: Peptide Group Buy PGB ($1.08), Pure Tested Peptides ($3.33), Orbitrex Peptides ($4.33). 0 of them publish a lab report (COA) for Tesofensine; compare lab scores and reports in the table above before buying.
Is Tesofensine FDA approved?
Investigational in most countries, including the US.
Can Tesofensine be compounded in the US?
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Compounding status for every peptide.
Does Tesofensine work? What does the research say?
Evidence grade B (some human evidence), from 8 papers: One 24-week phase 2 obesity RCT (203 people, under a Lancet expression of concern) plus pooled neurology trials show weight loss; no phase 3 data. Tesofensine (a small-molecule triple monoamine reuptake inhibitor, not a peptide) produced about 4.5-10.6% weight loss vs 2% with placebo in one 24-week phase 2 RCT of 203 people and modest weight loss in pooled neurology trials, but it raises heart rate, the key obesity trial later received a Lancet expression of concern, and a letter flagged under-reporting of its adverse effects; no phase 3 results appear in the candidates. See the papers.
Are there clinical trials of Tesofensine?
ClinicalTrials.gov lists 11 registered trials of Tesofensine: 0 active, 11 completed, 4 with posted results. Examples: Study to Investigate the Pharmacokinetic Profile (Completed, Phase 1, 60 people); Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (Completed, Phase 2, 60 people); 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO) (Completed, Phase 2, 21 people).
What dose of Tesofensine was used in studies?
Tesofensine is studied in people. adults with obesity (BMI 30-40) on an energy-restricted diet (phase 2): 0.25, 0.5 or 1.0 mg once daily; patients with Parkinson's or Alzheimer's disease (pooled 4 RCTs, no diet program): 0.125, 0.25, 0.5 or 1.0 mg once daily; patients with advanced Parkinson disease and motor fluctuations: 0.125, 0.25, 0.5 or 1 mg once daily. These are amounts used in published studies or official labels, not a recommendation.
What are the side effects of Tesofensine?
Reported in the research: Increased heart rate; Dry mouth, nausea, constipation, diarrhea; Insomnia; Neuropsychiatric adverse events (higher doses). The main obesity trial is under a Lancet expression of concern, and adverse effects may have been under-reported.